2015
Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. European Journal Of Gynaecological Oncology 2015, 36: 260-7. PMID: 26189250.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPhosphoric Monoester HydrolasesPrognosisProportional Hazards ModelsPTEN PhosphohydrolaseTumor Suppressor Protein p53Young AdultConceptsAberrant p53 expressionOvarian cancerP53 expressionHazard ratioLoss of PTENOvarian tumorsOvarian cancer tissue samplesEndometrioid ovarian tumorsProtein expressionSurvival hazard ratioEpithelial ovarian tumorsPoor disease outcomePossible prognostic roleProportional hazards modelCancer tissue samplesPrognostic roleEndometrioid tumorsEndometrioid subtypePrognostic valuePoor prognosisSerous subtypeProtein immunohistochemistryDisease outcomeTissue microarrayHazards model
2013
Type I and II Endometrial Cancers: Have They Different Risk Factors?
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Group T, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV, Kolonel LN, Henderson BE, Hankinson SE, Håkansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II Endometrial Cancers: Have They Different Risk Factors? Journal Of Clinical Oncology 2013, 31: 2607-2618. PMID: 23733771, PMCID: PMC3699726, DOI: 10.1200/jco.2012.48.2596.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAge FactorsAgedBiopsy, NeedleCarcinoma, EndometrioidCase-Control StudiesCohort StudiesConfidence IntervalsContraceptives, OralDatabases, FactualDiabetes MellitusDisease-Free SurvivalEndometrial NeoplasmsFemaleHumansImmunohistochemistryMiddle AgedNeoplasm InvasivenessNeoplasm StagingObesityOdds RatioRisk FactorsSensitivity and SpecificitySmokingSurvival AnalysisConceptsType II tumorsII tumorsRisk factorsEndometrial cancerOdds ratioHigh-grade endometrioid tumorsEndometrial cancer risk factorsType IEndometrial Cancer ConsortiumEndometrial cancer typesType I tumorsEndometrial cancer casesOral contraceptive useRisk factor patternsBody mass indexCancer risk factorsCommon etiologic factorCase-control studyDifferent risk factorsEndometrioid tumorsI tumorsMass indexCigarette smokingPooled analysisEtiologic factors
2009
Molecular markers and death from prostate cancer.
Concato J, Jain D, Uchio E, Risch H, Li WW, Wells CK. Molecular markers and death from prostate cancer. Annals Of Internal Medicine 2009, 150: 595-603. PMID: 19414838, DOI: 10.7326/0003-4819-150-9-200905050-00005.Peer-Reviewed Original ResearchConceptsProstate-specific antigen levelProstate cancerLong-term riskAntigen levelsMicrovessel densityMedian prostate-specific antigen levelIncreased long-term riskVeterans Affairs Healthcare SystemIncident prostate cancerObservational cohort studyProportional hazards analysisTime of diagnosisHigher microvessel densityVeterans Health AdministrationBcl-2Years of ageProstate cancer biopsiesClinical care recordsClinical characteristicsCohort studyPatient ageMedian ageComorbid conditionsHistologic gradeResidual confounding
2008
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression
Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF, Chow WH. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes & Control 2008, 20: 361-368. PMID: 18989634, PMCID: PMC2726999, DOI: 10.1007/s10552-008-9250-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAnti-Inflammatory Agents, Non-SteroidalBody Mass IndexCarcinoma, Squamous CellCardiaCase-Control StudiesConfidence IntervalsEsophageal NeoplasmsGastroesophageal RefluxHumansImmunohistochemistryLogistic ModelsMiddle AgedMulticenter Studies as TopicOdds RatioPopulation SurveillanceRisk FactorsSmokingStomach NeoplasmsTumor Suppressor Protein p53United StatesConceptsBody mass indexNon-steroidal anti-inflammatory drugsGastroesophageal reflux diseaseRisk factorsP53 overexpressionGastric cancerCigarette smokingReflux diseaseMass indexNon-steroidal anti-inflammatory drug useTumor subtypesPopulation-based case-control studyAnti-inflammatory drug useNon-cardia gastric adenocarcinomaGastro-esophageal reflux diseaseLarger body mass indexNon-cardia gastric cancerEsophageal squamous cell carcinomaTumor p53 overexpressionRisk factor profileSquamous cell carcinomaRisk of subtypesCase-control studyAnti-inflammatory drugsP53 protein overexpression
2007
Molecular markers and mortality in prostate cancer
Concato J, Jain D, Li WW, Risch HA, Uchio EM, Wells CK. Molecular markers and mortality in prostate cancer. BJU International 2007, 100: 1259-1263. PMID: 17850375, DOI: 10.1111/j.1464-410x.2007.07136.x.Peer-Reviewed Original ResearchConceptsProstate cancerPrognostic factorsMedical recordsMicrovessel densityMedian prostate-specific antigen levelProstate-specific antigen levelVeterans Affairs Medical CenterIncident prostate cancerLong-term mortalityCommunity-based populationPotential prognostic factorsTraditional prognostic factorsHigher microvessel densityTraditional clinical factorsAvailable medical recordsIndependent effectsBcl-2 stainingClinical factorsIndependent predictorsMedian ageOverall mortalityAdjusted analysisAntigen levelsMedical CenterAmbulatory care